Literature DB >> 17259297

Prophylactic HPV vaccines.

Margaret Stanley.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17259297      PMCID： PMC1972442          DOI： 10.1136/jcp.2006.040568

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  32 in total

1.  Carcinogenicity of human papillomaviruses.

Authors:  Vincent Cogliano; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Secretan; Fatiha El Ghissassi
Journal:  Lancet Oncol       Date:  2005-04       Impact factor: 41.316

2.  Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.

Authors:  R Kirnbauer; L M Chandrachud; B W O'Neil; E R Wagner; G J Grindlay; A Armstrong; G M McGarvie; J T Schiller; D R Lowy; M S Campo
Journal:  Virology       Date:  1996-05-01       Impact factor: 3.616

3.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Authors:  Sandra L Giannini; Emmanuel Hanon; Philippe Moris; Marcelle Van Mechelen; Sandra Morel; Francis Dessy; Marc A Fourneau; Brigitte Colau; Joann Suzich; Genevieve Losonksy; Marie-Thérèse Martin; Gary Dubin; Martine A Wettendorff
Journal:  Vaccine       Date:  2006-06-19       Impact factor: 3.641

Review 4.  Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling.

Authors:  Sue J Goldie; Jeremy D Goldhaber-Fiebert; Geoffrey P Garnett
Journal:  Vaccine       Date:  2006-08-31       Impact factor: 3.641

5.  Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16.

Authors:  X S Chen; R L Garcea; I Goldberg; G Casini; S C Harrison
Journal:  Mol Cell       Date:  2000-03       Impact factor: 17.970

Review 6.  HPV vaccines.

Authors:  Margaret Stanley
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2005-12-13       Impact factor: 5.237

7.  Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.

Authors:  Stan L Block; Terry Nolan; Carlos Sattler; Eliav Barr; Katherine E D Giacoletti; Colin D Marchant; Xavier Castellsagué; Steven A Rusche; Suzanne Lukac; Janine T Bryan; Paul F Cavanaugh; Keith S Reisinger
Journal:  Pediatrics       Date:  2006-11       Impact factor: 7.124

8.  Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.

Authors:  R C Rose; R C Reichman; W Bonnez
Journal:  J Gen Virol       Date:  1994-08       Impact factor: 3.891

9.  Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Authors:  Denise Nardelli-Haefliger; Daniel Wirthner; John T Schiller; Douglas R Lowy; Allan Hildesheim; Françoise Ponci; Pierre De Grandi
Journal:  J Natl Cancer Inst       Date:  2003-08-06       Impact factor: 13.506

10.  Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.

Authors:  Ruanne V Barnabas; Päivi Laukkanen; Pentti Koskela; Osmo Kontula; Matti Lehtinen; Geoff P Garnett
Journal:  PLoS Med       Date:  2006-04-04       Impact factor: 11.069
View more
  7 in total

Review 1.  Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.

Authors:  Paul L McCormack; Elmar A Joura
Journal:  Drugs       Date:  2010-12-24       Impact factor: 9.546

2.  Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years.

Authors:  Young-Jae Kim; Kyung-Tai Kim; Jae-Hoon Kim; Soon-Do Cha; Jae Weon Kim; Duk-Soo Bae; Joo-Hyun Nam; Woong-Shick Ahn; Ho-Sun Choi; Timothy Ng; Dan Bi; Jin-Ju OK; Dominique Descamps; Hans L Bock
Journal:  J Korean Med Sci       Date:  2010-07-21       Impact factor: 2.153

Review 3.  Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

Authors:  Valerie P O'Brien; Thomas J Hannan; Hailyn V Nielsen; Scott J Hultgren
Journal:  Microbiol Spectr       Date:  2016-02

4.  Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines.

Authors:  Roman Prymula; Ioana Anca; Francis André; Mustafa Bakir; Hanna Czajka; Irja Lutsar; Zsófia Mészner; Nuran Salman; Pavol Simurka; Vytautas Usonis
Journal:  Eur J Pediatr       Date:  2009-03-20       Impact factor: 3.183

Review 5.  Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix].

Authors:  Susan J Keam; Diane M Harper
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  Anti-cancer vaccines - a one-hit wonder?

Authors:  Justin K H Liu
Journal:  Yale J Biol Med       Date:  2014-12-12

7.  The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis.

Authors:  Herney Andrés García-Perdomo; Julio Cesar Osorio; Adrian Fernandez; James Alejandro Zapata-Copete; Andrés Castillo
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.